It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
German Leaked Report: COVID19 no worse than 2017-18 flu in Germany.
www.strategic-culture.org...
Original report in German
ichbinanderermeinung.de...
Dr. Birx is not working toward herd immunity except via vaccine!
www.politico.com...
New article analyzing the COVID19 disease.
[Read to test how much of this RINGS BELLS in your head as being assumptions]
Much of this is February style “Never before seen” hyperbole.
www.mdpi.com...
Must Read Article/Opinion piece! (Thanks Steven!)
off-guardian.org...
2nd must read for all of us!
off-guardian.org...
The Irony of the title of this page. Here you can find some nice #s.
www.cdc.gov...
Zinc again, just so you are aware.
www.sciencedirect.com...
Goes well with this paper from yesterday:
www.publichealthpolicyjournal.com...
DrRath foundation nutritional research on Immune system and micronutrients and trace minerals!
www.dr-rath-foundation.org...
www.drrathresearch.org...
Dept of Justice report on Vaccine Damage Comp. TM like AstroZen.
vaccineimpact.com...
RT news article (YES, I KNOW) written by UK MD; IFR and CFR.
www.rt.com...
NEJM Fauci editorial stating incorrect CFR for flu!?
www.nejm.org...
Bradykinin Hypothesis
elifesciences.org...
6. Bats are considered as distinct from other heterotherms in that, at all seasons of the year, their resting temperature and metabolic rate is dependent on the ambient temperature. This also is due to their lack of thermoregulation. They are the only mammals in which the resting metabolism is a direct function of the body temperature, rather than of the ambient temperature. Nevertheless, when active, they can maintain body temperatures of 40° C. or above.
AVM Biotechnology is led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and three discoveries in clinical trials. Dr. Deisher presented on the TrialSite Podcast recently.
AVM0703 is a novel and proprietary formulation of high concentration of dexamethasone. In addition to its recognized immunomodulatory properties, an acute high or suprapharmacologic dose of AVM0703 mobilizes highly active Natural Killer T- (NKT) and cytotoxic T- cells and dendritic cells. Within 6 hours of a single administration, there is evidence that AVM0703 “kick-starts” additional NKT cell activation. These cells have robust activity against very aggressive difficult-to-treat cancer models; this is directly relevant to COVID-19- and Influenza-mediated ARDS because NKT cells are programmed to eliminate abnormal cells, whether cancer or virus-infected.
originally posted by: puzzled2
FDA Authorizes Seattle-based AVM Biotechnology to Proceed with Clinical Trials in COVID-19
Good News,
AVM Biotechnology is led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and three discoveries in clinical trials. Dr. Deisher presented on the TrialSite Podcast recently.
6 hours for treatment of any strain of virus corona flu or cancer ( already approved for cancer ).
AVM0703 is a novel and proprietary formulation of high concentration of dexamethasone. In addition to its recognized immunomodulatory properties, an acute high or suprapharmacologic dose of AVM0703 mobilizes highly active Natural Killer T- (NKT) and cytotoxic T- cells and dendritic cells. Within 6 hours of a single administration, there is evidence that AVM0703 “kick-starts” additional NKT cell activation. These cells have robust activity against very aggressive difficult-to-treat cancer models; this is directly relevant to COVID-19- and Influenza-mediated ARDS because NKT cells are programmed to eliminate abnormal cells, whether cancer or virus-infected.
The French health ministry has reported 10,569 new cases in 24 hours, down from the previous day’s record increase of 13,498. 12 more deaths were registered in the past 24 hours, with the death toll rising to 31,585. The latest increase in deaths from yesterday’s toll may reflect late-arriving data for earlier fatalities, according to Reuters.
Devi Lalita Sridhar (born 1984) is a Professor and Chair of Global Public Health at the University of Edinburgh. Her research considers the effectiveness of public health interventions and how to improve developmental assistance for health.[1][3][4] Sridhar previously worked at the University of Oxford. She has written two books, The Battle Against Hunger: Choice, Circumstance and the World Bank (2008) and Governing Global Health: Who Runs the World and Why? (2017).